French regulator fines Novo Nordisk and Eli Lilly $2 million for misleading weight‑loss drug ads
France’s medicines authority imposed fines totaling roughly $2 million on Novo Nordisk and Eli Lilly for alleged misleading advertising of their obesity treatments Wegovy and Mounjaro. The penalties reflect growing regulatory scrutiny as competition intensifies in the lucrative weight‑loss drug market.
რეკლამა: Article Inline